Medtronic Debt-to-Assets Ratio Growth & History (MDT)
Medtronic's debt-to-assets ratio was 0.29 for fiscal 2026.
View full Medtronic company overviewMedtronic annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-04-24 | 0.29 | 0.00 | +0.80% |
| 2025 | 2025-04-25 | 0.29 | 0.00 | +0.87% |
| 2024 | 2024-04-26 | 0.29 | 0.01 | +3.61% |
| 2023 | 2023-04-28 | 0.28 | 0.05 | +19.58% |
| 2022 | 2022-04-29 | 0.23 | −0.06 | −20.66% |
| 2021 | 2021-04-30 | 0.29 | 0.01 | +3.00% |
| 2020 | 2020-04-24 | 0.29 | 0.00 | +0.87% |
| 2019 | 2019-04-26 | 0.28 | 0.00 | +0.53% |
| 2018 | 2018-04-27 | 0.28 | −0.05 | −15.75% |
| 2017 | 2017-04-28 | 0.33 | 0.02 | +7.71% |
| 2016 | 2016-04-29 | 0.31 | −0.02 | −6.97% |
| 2015 | 2015-04-24 | 0.33 | 0.06 | +22.76% |
| 2014 | 2014-04-25 | 0.27 | — | — |
Medtronic quarterly debt-to-assets ratio
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-07-31 | 0.27 | −0.01 | −4.59% |
| Q4 2026 | 2026-04-24 | 0.29 | 0.00 | +0.80% |
| Q3 2026 | 2026-01-31 | 0.31 | 0.04 | +15.10% |
| Q3 2026 | 2026-01-23 | 0.30 | 0.04 | +14.32% |
| Q2 2026 | 2025-10-24 | 0.30 | 0.03 | +10.88% |
| Q1 2026 | 2025-07-25 | 0.29 | −0.01 | −1.84% |
| Q4 2025 | 2025-04-25 | 0.29 | 0.00 | +0.87% |
| Q3 2025 | 2025-01-24 | 0.27 | 0.00 | +0.26% |
| Q2 2025 | 2024-10-25 | 0.27 | 0.01 | +3.70% |
| Q1 2025 | 2024-07-26 | 0.29 | 0.02 | +8.79% |
| Q4 2024 | 2024-04-26 | 0.29 | 0.01 | +3.61% |
| Q3 2024 | 2024-01-26 | 0.27 | 0.03 | +12.70% |
| Q2 2024 | 2023-10-27 | 0.26 | 0.04 | +18.40% |
| Q1 2024 | 2023-07-28 | 0.27 | 0.08 | +38.61% |
| Q4 2023 | 2023-04-28 | 0.28 | 0.05 | +19.58% |
| Q3 2023 | 2023-01-27 | 0.24 | −0.03 | −10.83% |
| Q2 2023 | 2022-10-28 | 0.22 | −0.06 | −20.25% |
| Q1 2023 | 2022-07-29 | 0.19 | −0.09 | −31.24% |
| Q4 2022 | 2022-04-29 | 0.23 | −0.06 | −20.66% |
| Q3 2022 | 2022-01-28 | 0.26 | −0.01 | −2.89% |
| Q2 2022 | 2021-10-29 | 0.28 | 0.01 | +3.05% |
| Q1 2022 | 2021-07-30 | 0.28 | 0.04 | +16.12% |
| Q4 2021 | 2021-04-30 | 0.29 | 0.01 | +3.00% |
| Q3 2021 | 2021-01-29 | 0.27 | −0.00 | −1.79% |
| Q2 2021 | 2020-10-30 | 0.27 | −0.01 | −4.28% |
| Q1 2021 | 2020-07-31 | 0.24 | −0.04 | −13.80% |
| Q4 2020 | 2020-04-24 | 0.29 | 0.00 | +0.87% |
| Q3 2020 | 2020-01-24 | 0.28 | 0.01 | +3.98% |
| Q2 2020 | 2019-10-25 | 0.28 | 0.01 | +5.35% |
| Q1 2020 | 2019-07-26 | 0.28 | 0.02 | +7.04% |
| Q4 2019 | 2019-04-26 | 0.28 | 0.00 | +0.53% |
| Q3 2019 | 2019-01-25 | 0.27 | −0.00 | −1.38% |
| Q2 2019 | 2018-10-26 | 0.27 | −0.01 | −2.21% |
| Q1 2019 | 2018-07-27 | 0.26 | 0.01 | +1.94% |
| Q4 2018 | 2018-04-27 | 0.28 | −0.05 | −15.75% |
| Q3 2018 | 2018-01-26 | 0.27 | 0.00 | +1.84% |
| Q2 2018 | 2017-10-27 | 0.27 | −0.02 | −6.84% |
| Q1 2018 | 2017-07-28 | 0.26 | −0.05 | −15.26% |
| Q4 2017 | 2017-04-28 | 0.33 | 0.02 | +7.71% |
| Q3 2017 | 2017-01-27 | 0.27 | −0.06 | −18.99% |
| Q2 2017 | 2016-10-28 | 0.29 | −0.03 | −8.17% |
| Q1 2017 | 2016-07-29 | 0.31 | −0.02 | −5.17% |
| Q4 2016 | 2016-04-29 | 0.31 | −0.02 | −6.97% |
| Q3 2016 | 2016-01-29 | 0.33 | — | — |
| Q2 2016 | 2015-10-30 | 0.32 | — | — |
| Q1 2016 | 2015-07-31 | 0.32 | — | — |
| Q4 2015 | 2015-04-24 | 0.33 | 0.06 | +22.76% |
| Q4 2014 | 2014-04-25 | 0.27 | — | — |
Medtronic debt-to-assets ratio trends
Over the last five fiscal years, Medtronic's debt-to-assets ratio decreased from 0.29 to 0.29, a change of −0.00. The latest reported quarter, Q1 2027, shows 0.27.
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Medtronic source filings ↗Community posts
Medtronic gains cardiac-software clearances across two ablation platforms
Medtronic ($MDT) obtained FDA clearance and a European CE mark for its latest Affera Prism-2 cardiac mapping software, alongside a CE mark for the PulseSelect ProxBox adapter and Proximity Indicator software. The Affera upgrade adds tools f ...
Medtronic’s GI Genius system shows gains in large clinical-practice study
Cosmo reported new results for GI Genius, the AI-assisted endoscopy system it develops and Medtronic ($MDT) commercializes. The cluster-randomized quality-improvement study covered more than 334,000 colonoscopies across 139 US Veterans Heal ...
Medtronic wins FDA clearance for LigaSure instrument on Hugo robot
Medtronic ($MDT) received FDA clearance for the LigaSure RAS Maryland jaw instrument for its Hugo robotic-assisted surgery system. The instrument brings the company’s vessel-sealing technology to the robotic platform and is designed to seal ...
Medtronic launches MiniMed share-exchange offer
Medtronic ($MDT) launched an exchange offer to split off at least 80.1% of MiniMed ($MMED), its former diabetes business. Investors can voluntarily exchange Medtronic shares for MiniMed stock at a 7% discount, subject to a cap of 4.5939 Min ...
Medtronic begins European clinical use of its Stealth AXiS surgical system
Medtronic ($MDT) announced the first European procedures using its Stealth AXiS surgical system, with more than 23 procedures performed across seven sites in Germany, the UK, Italy and Spain. The initial experience includes spinal surgery. ...